Innovative data processing technologies allow for new form of medicine, called Personalized or Precision Medicine (PerMed), which is using information about a person’s genes, proteins, and environment to prevent, diagnose and treat diseases. Each type of cancer has its own genetic makeup, giving each tumor cell and tissue a unique character with specific tendencies and vulnerabilities.
The team has unveiled a neural stimulator that is less than a cubic millimeter in size that can be placed directly where desired and that is powered using an external induction-based system.
Carmot Therapeutics, (Berkeley, CA) announced that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA). As part of the agreement, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson’s disease and other selected disease areas.
For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
In a recently published paper, researchers outline the importance of REM sleep and the causes and consequences of loss of REM sleep.
New research reveals how a dysfunction in the brain's so-called self-digestion system leads to cell death in neurodegenerative disorders. The newly discovered mechanism may lead to new therapies for conditions such as Parkinson's and Alzheimer's disease.
Keele University researchers have designed a new dye that can be used to observe the electrical activity of neurons in the brain and could lead to finding a new and more efficient way of treating neurological diseases, as presented at the Society for Neuroscience annual conference in Washington, D.C. this week.
Loxo Oncology struck a deal with Germany-based Bayer AG to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55 billion for the Connecticut-based company.
Amgen’s VC wing has invested in Fortuna Fix to help move autologous neural stem cells into the clinic. The $25 million series B sets regenerative medicine startup Fortuna up to move candidates against Parkinson’s disease and spinal cord injury to clinical trials next year.
Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world's second-leading cause of blindness.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.